AbbVie scores crucial phase 3 wins with Humira follow-up SkyriziAbbVie is in a race against time as US patent expiry of its Humira inflammatory diseases blockbuster looms Share XAbbVie scores crucial phase 3 wins with Humira follow-up Skyrizihttps://pharmaphorum.com/news/abbvie-scores-crucial-phase-3-wins-with-humira-follow-up-skyrizi/
Seven future blockbuster drugs to look out for in 2019AbbVie’s rheumatoid arthritis drug upadacitinib is at the top of a new list of drugs due to launch Share XSeven future blockbuster drugs to look out for in 2019https://pharmaphorum.com/news/seven-future-blockbuster-drugs-to-look-out-for-in-2019/